Northwest Biotherapeutics Enters Material Definitive Agreement

Ticker: NWBO · Form: 8-K · Filed: 2024-11-01T00:00:00.000Z

Sentiment: neutral

Topics: material-agreement, financial-obligation

Related Tickers: NWBO

TL;DR

NWBO just signed a big deal, creating a new financial obligation. Keep an eye on this.

AI Summary

On October 31, 2024, Northwest Biotherapeutics, Inc. entered into a material definitive agreement, creating a direct financial obligation. The company, incorporated in Delaware, has its principal executive offices in Bethesda, Maryland.

Why It Matters

This filing indicates a significant new financial commitment or obligation for Northwest Biotherapeutics, which could impact its financial standing and future operations.

Risk Assessment

Risk Level: medium — Entering into new financial obligations can introduce financial risk, especially for companies in the pharmaceutical sector which often have high development costs.

Key Players & Entities

FAQ

What type of material definitive agreement did Northwest Biotherapeutics enter into?

The filing states that Northwest Biotherapeutics, Inc. entered into a material definitive agreement that created a direct financial obligation or an obligation under an off-balance sheet arrangement of a registrant.

When was the earliest event reported in this filing?

The earliest event reported in this filing occurred on October 31, 2024.

Where is Northwest Biotherapeutics, Inc. incorporated?

Northwest Biotherapeutics, Inc. is incorporated in Delaware.

What is the principal executive office address for Northwest Biotherapeutics, Inc.?

The principal executive offices are located at 4800 Montgomery Lane, Suite 800, Bethesda, Maryland 20814.

What is the Commission File Number for Northwest Biotherapeutics, Inc.?

The Commission File Number for Northwest Biotherapeutics, Inc. is 0-35737.

Filing Stats: 529 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-11-01 17:24:13

Key Financial Figures

Filing Documents

01

Item 1.01. Entry into a Material Definitive Agreement. Loan Entered Into On October 31, 2024, Northwest Biotherapeutics, Inc. (the "Company") entered into a Convertible Note (the "Loan Agreement") with an unrelated shareholder (the "Holder") in the amount of $5,000,000. The Loan Agreement has a maturity of 24 months and no payments are due until maturity. Interest accrues at a rate of 11% per annum. There is no original issue discount. The Holder may at any time elect to convert any or all of the amount then owed under the Loan Agreement into either common stock of the Company at a price per share of $0.30, and/or one or more shares of a non-dilutive financial instrument related to a gain contingency priced at $50,000 each, or any mix of stock and the financial instrument. The Loan Agreement contains customary default provisions. The funds will be used for the Company's ongoing business operations.

03

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information included in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NORTHWEST BIOTHERAPEUTICS, INC. Date: November 1, 2024 By: /s/ Linda Powers Name: Linda Powers Title: Chief Executive Officer and Chairman

View on Read The Filing